Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




PET, SPECT Infusion Enhancements Streamline Infusion Scheduling

By HospiMedica International staff writers
Posted on 29 May 2012
Platforms have been developed for the controlled administration of molecular agents for single photon emission tomography (SPECT) as well as information technology (IT) enhancements to streamline positron emission tomography (PET) infusion scheduling.

Bayer Healthcare--Radiology & Interventional (Tarrytown, NY, USA) will present new device technologies at the annual meeting of the Society of Nuclear Medicine (SNM) in Miami (FL, USA), June 9-13, 2012. More...
The new technology includes enhancements to the Intego PET infusion system, as well as developing platforms for controlled administration of molecular agents for SPECT and small animal imaging procedures.

In PET, the Medrad Intego system is a worldwide market leader and the only US Food and Drug Administration (FDA)-cleared system for administration of 18F-fluorodeoxyglucose (FDG) and 18F-sodium fluoride (NaF). Bayer has continued to advance and evolve the Intego platform since its launch in 2008, including adding software features, expanding compatibility and indications, and considerably reducing the size of the device. At SNM, Bayer plans to demonstrate Certegra informatics systems for Intego, including wireless integration to hospital information systems/radiology information systems/picture archiving and communication systems (HIS/RIS/PACS), which simplify downloading the PET modality worklist as an infusion schedule and sending infusion results to PACS. This new capability will replace several manual processes, which subsequently will streamline workflow and improve efficiency for PET imaging clinics.

Doug Descalzi, Bayer senior director of molecular devices, said, “Automated, controlled injection of molecular agents not only has safety and workflow benefits for staff, it can lead to improvements in patient care and help clinicians

Moreover, the company will present developing technologies for controlled administration of low energy radiopharmaceuticals and for small animal molecular imaging in a scientific exhibition.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer, AG (Leverkusen, Germany, is one of the world’s leading companies in the healthcare and medical products industry. The company combines the global activities of the animal health, consumer care, medical care, and pharmaceuticals divisions.

Related Links:

Bayer Healthcare



Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Heavy-Duty Wheelchair Scale
6495 Stationary
Radiology System
Riviera SPV AT
Portable Jaundice Management Device
Nymphaea
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.